Fintepla - (2.2 mg/mL ; Solution)

Generic Name	Fenfluramine Hydrochloride	Innovator	Zogenix
Dosage	2.2 mg/mL ; Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** / *********	*** **, ****	******* / ********* ** ***** ** ******	****	******* *** **** *** *** ****
*****	** / **	*** **, ****	******* / ********* ** ***** ** *****	****	******* *** **** *** *** ****

Chronology Of Events